Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment
2007

LXR Agonists Reduce Amyloid and Inflammation in Alzheimer's Disease Mice

Sample size: 10 publication 10 minutes Evidence: moderate

Author Information

Author(s): Lefterov Iliya, Bookout Angie, Wang Zhu, Staufenbiel Matthias, Mangelsdorf David, Koldamova Radosveta

Primary Institution: University of Pittsburgh

Hypothesis

Can LXR agonists inhibit amyloid deposition and inflammation in APP23 mice?

Conclusion

LXR agonists can alleviate Alzheimer's disease pathology by reducing amyloid deposition and inflammation in the brain.

Supporting Evidence

  • LXR agonists increased the expression of genes related to lipid metabolism.
  • T0 treatment decreased the level of insoluble Aβ in APP23 mice.
  • LXR activation suppressed inflammatory responses in microglia and astrocytes.
  • Prolonged T0 treatment significantly reduced pro-inflammatory gene expression.

Takeaway

This study shows that a special treatment can help mice with Alzheimer's by reducing harmful substances in their brains.

Methodology

APP23 mice were treated with LXR agonist T0901317 for various durations, and gene expression was analyzed using RT-QPCR and gene arrays.

Potential Biases

Potential bias in interpreting results due to the use of a single mouse model.

Limitations

The study primarily focuses on a specific mouse model and may not fully represent human Alzheimer's disease.

Participant Demographics

6-month old APP23 transgenic mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1750-1326-2-20

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication